Quince Therapeutics (QNCX) AI Stock Analysis

• Market Cap: $90.24M
• Dividend Yield: N/A
• Average Volume (3M): 227.47K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.13
• Revenue Growth: N/A
• EPS Growth: 13.49%
• Country: US
• Employees: 36
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 53,713,800
• 10 Day Avg. Volume: 272,482
• 30 Day Avg. Volume: 227,473
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.66
• Enterprise Value/Revenue: 356.03
• Enterprise Value/Gross Profit: -866.84
• Enterprise Value/Ebitda: -1.21
• 1Y Price Target: $8.00
• Price Target Upside: 373.37% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 31 Underperform
• Price Target: ―

Quince Therapeutics faces substantial financial challenges with no revenue, consistent losses, and negative cash flows, severely impacting its financial performance score. Technical analysis provides mixed signals, with some indicators suggesting potential momentum but overall bearish trends. Valuation remains unattractive due to the negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Clinical Trials Progress

The ongoing P3 study of eDSP in ataxia-telangiectasia has exceeded 75% enrollment, indicating strong progress.

Patient Management

All patients that completed the trial have chosen to transition to the open label extension study, suggesting effective management of steroid delivery.

Technology Advantage

The AIDE technology allows for the effective delivery of dexamethasone with fewer safety concerns compared to traditional methods.

Negative Factors

Enrollment Challenges

Enrollment in the P3 NEAT study is slower than expected, which has led management to consider concluding enrollment early.

Financial Performance

Quince reported 4Q24 and 2024 results with a net loss of ($12.5M) and ($56.8M), respectively, which included $25.4M in non-cash items.

Quince Therapeutics Business Overview & Revenue Model

Company Description

Quince Therapeutics (QNCX) is a biopharmaceutical company focused on developing innovative treatments for patients suffering from chronic and debilitating diseases. Operating within the healthcare and biotechnology sectors, Quince Therapeutics leverages advanced scientific research and cutting-edge technology to design and develop therapeutic solutions aimed at addressing unmet medical needs. The company's core products include a pipeline of drug candidates that target specific molecular pathways implicated in various diseases.

How the Company Makes Money

Quince Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products. Revenue is generated from sales of approved drugs, milestone payments, and royalties from partnerships or licensing agreements with larger pharmaceutical companies. In addition, the company may receive funding through research grants and collaborations with academic institutions or other biotech firms. Quince Therapeutics' earnings are significantly influenced by the successful progression of its drug candidates through clinical trials and obtaining necessary regulatory approvals.

Quince Therapeutics Financial Statement Overview

Summary

Quince Therapeutics faces significant financial challenges with no revenue generation, consistent losses, and substantial cash outflows. The company's balance sheet shows a manageable debt level but decreasing equity, raising concerns about long-term financial health. Without significant changes in revenue generation or cost management, the company may continue facing financial difficulties.

Income Statement

Quince Therapeutics reported no revenue over the past years, resulting in negative gross and net profit margins. The continuous negative EBIT and EBITDA margins highlight ongoing operational challenges in generating profitability. The lack of revenue growth further stresses the company's struggle to achieve financial stability.

Balance Sheet

The company's debt-to-equity ratio remains relatively low, reflecting modest leverage. However, the declining equity over time indicates potential financial instability. The equity ratio has been decreasing, showing a reduction in the company's financial buffer. Despite these challenges, the company maintains a significant cash balance relative to its debt.

Cash Flow

Quince Therapeutics has consistently negative free cash flow, indicating cash outflows exceed cash inflows. The operating cash flow to net income ratio is affected by the negative operating cash flow, suggesting difficulties in converting earnings into cash. The substantial negative free cash flow to net income ratio further emphasizes cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	168.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-69.00K	-186.00K	-322.00K	-175.00K	-344.00K	-332.00K
EBITDA	-49.36M	-56.55M	-31.26M	-49.89M	-89.97M	-78.56M
Net Income	-49.03M	-56.83M	-31.39M	-51.66M	-89.94M	-76.85M
Balance Sheet
Total Assets	117.21M	114.48M	167.90M	103.91M	133.23M	189.47M
Cash, Cash Equivalents and Short-Term Investments	34.71M	40.78M	75.06M	90.18M	106.80M	133.82M
Total Debt	17.38M	14.81M	13.81M	453.00K	1.16M	446.00K
Total Liabilities	105.47M	84.33M	82.82M	3.32M	14.64M	17.20M
Stockholders Equity	11.74M	30.15M	85.08M	100.59M	118.59M	172.26M
Cash Flow
Free Cash Flow	-29.93M	-32.16M	-18.45M	-44.17M	-63.11M	-50.87M
Operating Cash Flow	-29.34M	-31.90M	-18.29M	-44.04M	-62.93M	-50.82M
Investing Cash Flow	32.39M	21.91M	-5.76M	18.00M	58.95M	-52.43M
Financing Cash Flow	8.96M	-4.78M	143.00K	707.00K	6.81M	118.88M

Quince Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNCX, the sentiment is Neutral. The current price of 1.69 is below the 20-day moving average (MA) of 1.73, above the 50-day MA of 1.60, and above the 200-day MA of 1.50, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 50.81 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for QNCX.

Quince Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FBIO	54 Neutral	$57.96M	―	-47.67%	―	-28.23%	93.42%
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.82%	-2.28%
AGEN	43 Neutral	$144.98M	―	260.68%	―	-36.29%	36.16%
CYCC	38 Underperform	$14.08M	―	-276.72%	―	-96.88%	86.28%
OTLK	38 Underperform	$104.13M	―	<0.01%	―	―	―
QNCX	31 Underperform	$90.24M	―	-167.04%	―	―	13.49%